Zhong Jin Zai Xian·2026-03-30 14:32Core Insights - The company reported total revenue of RMB 173.43 billion and adjusted operating profit of RMB 4 billion for the fiscal year ending December 31, 2025 [1][2] - The overseas revenue reached RMB 94.86 billion, accounting for 54.7% of total revenue, an increase of 5.4 percentage points year-on-year [1][7] - The company aims to gradually restore profit levels to RMB 10 billion and reduce total liabilities to below RMB 60 billion [1][12] Financial Performance - The four core subsidiaries generated revenue of RMB 128.2 billion, representing 74% of total revenue [2] - The health sector subsidiary, Fosun Pharma, reported a net profit of RMB 3.371 billion, a year-on-year increase of 21.69% [2] - The insurance subsidiary, Fosun Portugal, achieved a net profit of EUR 201 million, up 15.8% year-on-year [2][8] Strategic Initiatives - The company is implementing a "streamlining and focusing on core business" strategy, resulting in a non-cash impairment charge of RMB 23.4 billion, primarily from real estate and non-core assets [2][3] - The company has invested RMB 7.8 billion in innovation, with seven innovative drugs approved for 16 indications domestically and internationally [4][5] Innovation and R&D - The company’s innovative drug revenue reached RMB 9.893 billion, a year-on-year increase of 29.59%, accounting for 33.16% of pharmaceutical business revenue [5] - The company has nearly 40 innovative drug clinical trials approved by regulatory agencies in China, the US, and Europe [5][6] Globalization Efforts - The company’s globalization strategy has evolved from "product export" to "system export," achieving significant breakthroughs in various dimensions [8] - The insurance segment has shown robust growth, with Fosun Portugal's gross premium income reaching EUR 6.53 billion, and net profit of EUR 201 million [8][9] ESG and Social Responsibility - The company has contributed to global malaria treatment, supplying over 440 million doses of its self-developed artemether injection [11] - The company received the highest MSCI ESG rating of AAA and was included in the S&P Global Sustainability Yearbook 2026 [11]